Annovis Accounts Payable vs Net Working Capital Analysis

ANVS Stock

USD 6.65 0.14 2.06%

Annovis Bio financial indicator trend analysis is way more than just evaluating Annovis Bio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Annovis Bio is a good investment. Please check the relationship between Annovis Bio Accounts Payable and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Annovis Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Annovis Stock please use our How to Invest in Annovis Bio guide.

Accounts Payable vs Net Working Capital

Accounts Payable vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Annovis Bio Accounts Payable account and Net Working Capital. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Annovis Bio's Accounts Payable and Net Working Capital is 0.17. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Annovis Bio, assuming nothing else is changed. The correlation between historical values of Annovis Bio's Accounts Payable and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Annovis Bio are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Accounts Payable i.e., Annovis Bio's Accounts Payable and Net Working Capital go up and down completely randomly.

Correlation Coefficient

0.17

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Annovis Bio obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Annovis Bio are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Net Working Capital

Most indicators from Annovis Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Annovis Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Annovis Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Annovis Stock please use our How to Invest in Annovis Bio guide.At this time, Annovis Bio's Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 16.2 M in 2024, whereas Discontinued Operations is likely to drop (6.3 M) in 2024.

	2021	2022	2023	2024 (projected)
Research Development	8.5M	16.5M	38.8M	40.7M
Other Operating Expenses	14.5M	25.5M	45.0M	47.3M

Research Development Other Operating Expenses

Annovis Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Net Receivables	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Other Assets	Good Will	Net Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Net Invested Capital
Total Assets		0.47	0.62	0.92	0.75	-0.36	0.52	0.93	0.21	-0.03	-0.16	0.65	-0.04	0.99	0.12	-0.15	0.23	0.19	-0.15	-0.92	0.92	0.67	0.62	-0.34	0.7	0.89
Other Current Liab	0.47		0.63	0.16	0.83	-0.89	0.29	0.42	-0.2	-0.27	-0.05	0.89	0.67	0.5	-0.42	-0.23	-0.2	-0.15	-0.3	-0.39	0.38	0.78	0.81	0.44	0.86	0.28
Total Current Liabilities	0.62	0.63		0.42	0.59	-0.47	0.91	0.35	0.54	0.13	0.01	0.52	0.39	0.55	0.36	-0.2	0.57	0.49	-0.26	-0.32	0.32	0.45	0.53	0.14	0.51	0.29
Total Stockholder Equity	0.92	0.16	0.42		0.5	-0.03	0.41	0.89	0.21	0.1	-0.19	0.36	-0.42	0.91	0.24	0.0	0.21	0.15	0.02	-0.9	0.9	0.44	0.39	-0.64	0.43	0.93
Net Tangible Assets	0.75	0.83	0.59	0.5		-0.88	0.34	0.69	-0.05	-0.09	-0.22	0.98	0.45	0.76	-0.24	-0.12	-0.03	0.05	-0.21	-0.66	0.65	0.94	0.86	0.23	0.98	0.54
Retained Earnings	-0.36	-0.89	-0.47	-0.03	-0.88		-0.18	-0.31	0.15	0.17	0.13	-0.93	-0.75	-0.37	0.43	0.2	0.15	0.06	0.32	0.27	-0.26	-0.84	-0.8	-0.61	-0.89	-0.12
Accounts Payable	0.52	0.29	0.91	0.41	0.34	-0.18		0.19	0.82	0.36	0.02	0.22	0.19	0.41	0.69	-0.13	0.85	0.76	-0.16	-0.17	0.16	0.18	0.22	0.03	0.21	0.16
Cash	0.93	0.42	0.35	0.89	0.69	-0.31	0.19		-0.11	-0.24	-0.14	0.63	-0.12	0.97	-0.15	-0.15	-0.1	-0.14	-0.13	-1.0	1.0	0.68	0.63	-0.45	0.7	0.97
Net Receivables	0.21	-0.2	0.54	0.21	-0.05	0.15	0.82	-0.11		0.52	-0.06	-0.18	-0.03	0.09	0.81	-0.2	0.98	0.82	-0.22	0.12	-0.12	-0.2	-0.21	-0.02	-0.19	-0.11
Inventory	-0.03	-0.27	0.13	0.1	-0.09	0.17	0.36	-0.24	0.52		-0.15	-0.24	-0.36	-0.13	0.69	0.57	0.49	0.67	0.53	0.24	-0.25	-0.28	-0.33	0.08	-0.25	-0.24
Other Current Assets	-0.16	-0.05	0.01	-0.19	-0.22	0.13	0.02	-0.14	-0.06	-0.15		-0.17	0.12	-0.16	-0.06	-0.08	-0.06	-0.11	-0.05	0.15	-0.14	-0.19	0.19	0.06	-0.17	-0.13
Other Stockholder Equity	0.65	0.89	0.52	0.36	0.98	-0.93	0.22	0.63	-0.18	-0.24	-0.17		0.56	0.67	-0.39	-0.18	-0.17	-0.09	-0.27	-0.6	0.59	0.95	0.89	0.32	1.0	0.47
Total Liab	-0.04	0.67	0.39	-0.42	0.45	-0.75	0.19	-0.12	-0.03	-0.36	0.12	0.56		-0.04	-0.32	-0.37	0.01	0.02	-0.45	0.17	-0.17	0.39	0.46	0.83	0.5	-0.32
Total Current Assets	0.99	0.5	0.55	0.91	0.76	-0.37	0.41	0.97	0.09	-0.13	-0.16	0.67	-0.04		0.0	-0.17	0.1	0.05	-0.17	-0.96	0.96	0.7	0.66	-0.37	0.73	0.93
Intangible Assets	0.12	-0.42	0.36	0.24	-0.24	0.43	0.69	-0.15	0.81	0.69	-0.06	-0.39	-0.32	0.0		0.35	0.87	0.9	0.36	0.16	-0.15	-0.39	-0.41	-0.19	-0.39	-0.1
Common Stock	-0.15	-0.23	-0.2	0.0	-0.12	0.2	-0.13	-0.15	-0.2	0.57	-0.08	-0.18	-0.37	-0.17	0.35		-0.11	0.27	0.98	0.14	-0.14	-0.2	-0.22	0.0	-0.18	-0.12
Property Plant Equipment	0.23	-0.2	0.57	0.21	-0.03	0.15	0.85	-0.1	0.98	0.49	-0.06	-0.17	0.01	0.1	0.87	-0.11		0.88	-0.13	0.12	-0.12	-0.18	-0.2	-0.01	-0.17	-0.1
Other Assets	0.19	-0.15	0.49	0.15	0.05	0.06	0.76	-0.14	0.82	0.67	-0.11	-0.09	0.02	0.05	0.9	0.27	0.88		0.26	0.16	-0.17	-0.13	-0.21	0.14	-0.1	-0.18
Good Will	-0.15	-0.3	-0.26	0.02	-0.21	0.32	-0.16	-0.13	-0.22	0.53	-0.05	-0.27	-0.45	-0.17	0.36	0.98	-0.13	0.26		0.12	-0.12	-0.27	-0.31	-0.1	-0.26	-0.09
Net Debt	-0.92	-0.39	-0.32	-0.9	-0.66	0.27	-0.17	-1.0	0.12	0.24	0.15	-0.6	0.17	-0.96	0.16	0.14	0.12	0.16	0.12		-1.0	-0.65	-0.61	0.48	-0.67	-0.98
Cash And Short Term Investments	0.92	0.38	0.32	0.9	0.65	-0.26	0.16	1.0	-0.12	-0.25	-0.14	0.59	-0.17	0.96	-0.15	-0.14	-0.12	-0.17	-0.12	-1.0		0.64	0.61	-0.49	0.66	0.98
Common Stock Total Equity	0.67	0.78	0.45	0.44	0.94	-0.84	0.18	0.68	-0.2	-0.28	-0.19	0.95	0.39	0.7	-0.39	-0.2	-0.18	-0.13	-0.27	-0.65	0.64		0.89	0.1	0.96	0.56
Common Stock Shares Outstanding	0.62	0.81	0.53	0.39	0.86	-0.8	0.22	0.63	-0.21	-0.33	0.19	0.89	0.46	0.66	-0.41	-0.22	-0.2	-0.21	-0.31	-0.61	0.61	0.89		0.15	0.9	0.52
Non Current Liabilities Total	-0.34	0.44	0.14	-0.64	0.23	-0.61	0.03	-0.45	-0.02	0.08	0.06	0.32	0.83	-0.37	-0.19	0.0	-0.01	0.14	-0.1	0.48	-0.49	0.1	0.15		0.24	-0.64
Capital Surpluse	0.7	0.86	0.51	0.43	0.98	-0.89	0.21	0.7	-0.19	-0.25	-0.17	1.0	0.5	0.73	-0.39	-0.18	-0.17	-0.1	-0.26	-0.67	0.66	0.96	0.9	0.24		0.54
Net Invested Capital	0.89	0.28	0.29	0.93	0.54	-0.12	0.16	0.97	-0.11	-0.24	-0.13	0.47	-0.32	0.93	-0.1	-0.12	-0.1	-0.18	-0.09	-0.98	0.98	0.56	0.52	-0.64	0.54

Click cells to compare fundamentals

Annovis Bio Account Relationship Matchups

Annovis Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.1M	8.1M	46.0M	36.0M	10.2M	14.9M
Other Current Liab	776.9K	236.5K	818.4K	3.7M	3.0M	3.1M
Total Current Liabilities	2.0M	578.4K	1.5M	7.7M	4.3M	3.0M
Total Stockholder Equity	(8.6M)	7.5M	44.5M	28.3M	(7.8M)	(7.4M)
Net Tangible Assets	(7.6M)	(8.6M)	7.5M	44.5M	51.2M	53.7M
Retained Earnings	(8.8M)	(14.2M)	(28.7M)	(54.1M)	(110.3M)	(104.7M)
Accounts Payable	1.2M	341.9K	688.1K	4.0M	1.3M	1.5M
Cash	1.9K	8.1M	45.7M	28.4M	5.8M	9.4M
Other Current Assets	745.7M	38.2K	72.8K	104.9K	41.5K	39.5K
Other Stockholder Equity	200.6K	21.8M	73.2M	82.4M	102.5M	107.6M
Total Liab	9.7M	578.4K	1.5M	7.7M	18.0M	18.9M
Total Current Assets	747.5K	8.1M	46.0M	36.0M	10.2M	12.9M
Net Debt	497.9K	(8.1M)	(45.7M)	(28.4M)	(5.8M)	(6.0M)
Cash And Short Term Investments	1.9K	8.1M	45.7M	28.4M	5.8M	5.5M
Common Stock Shares Outstanding	6.8M	6.3M	7.6M	8.2M	9.0M	7.3M
Liabilities And Stockholders Equity	1.1M	8.1M	46.0M	36.0M	10.2M	16.0M
Non Current Liabilities Total	7.7M	341.9K	688.1K	4.0M	13.7M	14.4M
Capital Surpluse	192.1K	200.6K	21.8M	73.2M	84.2M	88.4M
Net Invested Capital	(8.1M)	7.5M	44.5M	28.3M	(7.8M)	(7.4M)
Net Working Capital	(1.3M)	7.5M	44.5M	28.3M	5.9M	5.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Annovis Stock Analysis

When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC